Interviews with Summit Director Edgardo S. Santos Castillero, MD, FACP, FASCO
NOSCM 2024 | New Orleans Summer Cancer Meeting

NOSCM-071924 - Dr E.dgardo S. Santos with Dr Ahmed Zakari Interview

Drs. Santos and Zakari highlighted that tumor-informed ctDNA testing in oligometastatic colorectal cancer can detect minimal residual disease—helping identify patients unlikely to benefit from adjuvant chemotherapy—with repeat assays raising sensitivity to 80–85%. They also noted ASCO’s recent preference for fluorouracil in upper GI adenocarcinomas and underscored ctDNA’s prognostic value in the GALAXY trial.

Presented at PRIMO 2025 | Practical Recommendations in Immuno & Molecular Oncology

The Changing Face of Cancer Therapeutics
Session Chair: Sanjiv S. Agarwala, MD FASCO

The Role of Social Media in OncologyModerator: Don Dizon, MD, FACP, FASCO
Panel: Sanjiv Agarwala, MD, FASCO | Sanjay Juneja, MD | Luis E. Raez, MD, FACP, FASCO

Presented at PRIMO 2025 | Practical Recommendations in Immuno & Molecular Oncology

The Changing Face of Cancer Therapeutics

Session Chair: Sanjiv S. Agarwala, MD FASCO

Speaker: Sanjay Juneja, MD

Interviews with Summit Director Edgardo S. Santos Castillero, MD, FACP, FASCO
NOSCM 2024 | New Orleans Summer Cancer Meeting

NOSCM-071924 - Dr E Santos with Dr Benedetto Interview

Dr. Benedetto underscored that maintaining dose intensityand following biomarkers are critical to preventing relapses in rare testicularcancer, recommending sperm banking before treatment and annual post-treatmentfollow-ups. He also reassured that most patients can preserve fertility andachieve normal lifespans with experienced, guideline-driven care.

Breast Cancer Session

Presented at the 14th Annual WCS | Winter Cancer Symposium 2025

Ruta D. Rao, MD | Rush University Medical Center

Dr. Rao talks about the evolution of antibody drug conjugates (ADCs) for HER2-negative breast cancer, highlighting their role in revolutionizing chemotherapy. FDA approvals and NCCN guidelines for these ADCs were also addressed.

Lung Cancer Session

Presented at the 14th Annual WCS | Winter Cancer Symposium 2025

Sonam Puri, MD | Moffitt Cancer Center

Dr. Puri highlights the evolution of neoadjuvant, adjuvant, and perioperative immunotherapy for non-small cell lung cancer (NSCLC). The need for further clinical trials to optimize treatment and address logistical challenges was emphasized.

GU Malignancies and Brain Tumors

Presented at the 14th Annual WCS | Winter Cancer Symposium 2025

Catherine Fahey, MD, PhD | University of North Carolina at Chapel Hill

Dr. Fahey discusses targeted immunotherapy approaches for kidney cancer, focusing on clear cell renal cell carcinoma (ccRCC). She highlights the evolution of treatments, emphasizing the use of immune checkpoint inhibitors and targeted therapies since the 2000s.

Advances in Melanoma-Gyn Oncology-Sarcomas and Head and Neck Cancer

Presented at the 14th Annual WCS | Winter Cancer Symposium 2025
Speaker: Meghan J. Mooradian, MD | Massachusetts General Hospital

Dr. Mooradian discusses recent advancements in melanoma treatment. She highlighted the evolution of immunotherapy, including the approval of nivolumab and erlatinib in 2022, and the effectiveness of dual ICI therapy. TIL therapy and cryoablation were also discussed as promising strategies for resistant tumors.